A new trial will evaluate whether integrating autonomous AI screening for diabetic retinopathy into U.S. federally qualified ...
Conflicting studies on GLP-1 drugs’ vision impacts prompt calls for baseline eye exams and monitoring.
Robin Erickson has been covering high school sports since 2023 after graduating from Carroll College with a degree in Health Sciences. He began working in data operations at High School On SI before ...
Background Diabetic retinopathy (DR) is a common microvascular complication of diabetes that has the potential to progress to vision-threatening DR (VTDR) even in the absence of symptoms. Plasma ...
Objectives To investigate whether quantitative retinal markers, derived from multimodal retinal imaging, are associated with increased risk of mortality among individuals with proliferative diabetic ...
Hypoglycemia is linked to an increased risk for and progression of diabetic retinopathy, according to new research presented at The Retina Society (TRS) Annual Meeting 2025. Severe hypoglycemia is ...
Abstract: Diabetic Retinopathy (DR) is a leading cause of vision loss, where early and accurate diagnosis is essential for effective treatment. In this study, we propose a novel Deep Contrastive ...
Specialists can identify subtle changes in the retina before symptoms appear and apply treatments that can slow or stop vision loss. Ophthalmologists specialize in the diagnosis and treatment of ...
Some reassuring news for patients taking GLP-1 receptor agonists: Concerns that the drugs may cause retinopathy may be overblown. A new analysis of nearly 160,000 people with diabetes taking four ...
Survival models using EHR data predicted progression from NPDR or DME to PDR in type 2 diabetes patients. Key risk factors for progression included age, race, NPDR severity, and diabetic nephropathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback